tiprankstipranks
Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA
Want to see SNOA full AI Analyst Report?

Sonoma Pharmaceuticals (SNOA) Price & Analysis

352 Followers

SNOA Stock Chart & Stats

$3.78
-$0.06(-2.19%)
At close: 4:00 PM EST
$3.78
-$0.06(-2.19%)

Bulls Say, Bears Say

Bulls Say
Low Financial LeverageLow reported leverage (debt-to-equity ~0.14) reduces near-term solvency risk and gives management financial flexibility. With limited debt service obligations, Sonoma can prioritize commercial investment or absorb continued losses without immediate refinancing pressure, supporting operational resilience over the next several months.
Kenvue Supply AgreementThe multi-year Microcyn® manufacturing and supply agreement with Kenvue provides a durable commercial channel into the U.S. market. A defined term and renewal options deliver predictable demand and distribution reach, increasing planning visibility and the potential to scale volumes and improve unit economics over a multi-month to multi-year horizon.
Revenue Resilience & MarginsConsistent top-line growth and steady gross margins (~37–38%) indicate persistent demand for HOCl products and sustainable unit economics. This revenue resilience provides a base for operating leverage if sales scale further, making a future profitability inflection more achievable without relying solely on cost cuts.
Bears Say
Negative Cash FlowTrailing-twelve-month OCF and FCF remain materially negative, reflecting ongoing cash burn. Persistent negative cash generation constrains Sonoma's ability to fund commercialization, R&D, or working capital from operations, forcing reliance on external financing and creating execution risk if capital access tightens over the coming months.
Persistent UnprofitabilityDeep negative net margins and very poor returns on equity signal structural profitability issues. Continued losses erode equity and limit internal reinvestment capacity, meaning Sonoma must materially grow revenue or materially improve cost structure to achieve durable profitability and restore capital efficiency over a 2–6 month horizon.
Reliance On External FundingThe recent equity offering to raise roughly $3.5M underscores reliance on capital markets to sustain operations. Regularly tapping external financing is a structural vulnerability: it dilutes shareholders, depends on market access, and highlights that cash generation from operations remains insufficient for medium-term funding needs.

Sonoma Pharmaceuticals News

SNOA FAQ

What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was $0.85 and its highest was $6.92 in the past 12 months.
    What is Sonoma Pharmaceuticals’s market cap?
    Sonoma Pharmaceuticals’s market cap is $3.72M.
      When is Sonoma Pharmaceuticals’s upcoming earnings report date?
      Sonoma Pharmaceuticals’s upcoming earnings report date is Jul 15, 2026 which is in 53 days.
        How were Sonoma Pharmaceuticals’s earnings last quarter?
        Sonoma Pharmaceuticals released its earnings results on Feb 10, 2026. The company reported -$0.352 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.062.
          Is Sonoma Pharmaceuticals overvalued?
          According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Sonoma Pharmaceuticals pay dividends?
            Sonoma Pharmaceuticals does not currently pay dividends.
            What is Sonoma Pharmaceuticals’s EPS estimate?
            Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Sonoma Pharmaceuticals have?
            Sonoma Pharmaceuticals has 3,473,554 shares outstanding.
              What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
              Sonoma Pharmaceuticals reported an EPS of -$0.352 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went up 1.423%.
                Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
                Currently, no hedge funds are holding shares in SNOA
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Sonoma Pharmaceuticals

                  Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

                  Sonoma Pharmaceuticals (SNOA) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  China Pharma Holdings
                  RedHill Biopharma
                  Sunshine Biopharma
                  Shuttle Pharmaceuticals Holdings, Inc.

                  Ownership Overview

                  14.62%0.97%0.67%83.20%
                  14.62%
                  Insiders
                  0.67% Other Institutional Investors
                  83.20% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks